Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Mease

Showing results (111-120 of 175) with videos related to

Pageof 18
Sort By:
Arthritis Care & Research|May 13, 2010
The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severityFrederick Wolfe, Daniel J Clauw, Mary-Ann Fitzcharles, et al.
Nature Reviews. Rheumatology|February 16, 2021
Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus studyLourdes M Perez-Chada, Rebecca H Haberman, Vinod Chandran, et al.
ACR Open Rheumatology|August 1, 2024
Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled TrialsArthur Kavanaugh, Philip Mease, Laure Gossec, et al.
Drugs - Real World Outcomes|July 31, 2024
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor InhibitorsJessica A Walsh, Iris Lin, Ruizhi Zhao, et al.
Annals of the Rheumatic Diseases|March 19, 2018
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 studyPhilip Mease, Désirée van der Heijde, Robert Landewé, et al.
RMD Open|March 23, 2023
Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extensionLihi Eder, Dafna D Gladman, Philip Mease, et al.
Rheumatology and Therapy|December 7, 2020
Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X TrialAtul Deodhar, Philip Mease, Proton Rahman, et al.
The New England Journal of Medicine|October 19, 2017
Tofacitinib or Adalimumab versus Placebo for Psoriatic ArthritisPhilip Mease, Stephen Hall, Oliver FitzGerald, et al.
The Journal of Investigative Dermatology|January 26, 2025
Construct Validity of the IDEOM Musculoskeletal Questionnaire: An Instrument to Measure Musculoskeletal Symptoms in Patients with Psoriatic DiseaseLourdes M Perez-Chada, George Gondo, Carly Grant, et al.
Arthritis and Rheumatism|December 4, 2010
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trialPhilip Mease, Mark C Genovese, Geoffrey Gladstein, et al.
Pageof 18

Showing results (111-120 of 175) with videos related to

Sort By:
Pageof 18
Arthritis Care & Research|May 13, 2010
The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severityFrederick Wolfe, Daniel J Clauw, Mary-Ann Fitzcharles, et al.
Nature Reviews. Rheumatology|February 16, 2021
Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus studyLourdes M Perez-Chada, Rebecca H Haberman, Vinod Chandran, et al.
ACR Open Rheumatology|August 1, 2024
Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled TrialsArthur Kavanaugh, Philip Mease, Laure Gossec, et al.
Drugs - Real World Outcomes|July 31, 2024
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor InhibitorsJessica A Walsh, Iris Lin, Ruizhi Zhao, et al.
Annals of the Rheumatic Diseases|March 19, 2018
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 studyPhilip Mease, Désirée van der Heijde, Robert Landewé, et al.
RMD Open|March 23, 2023
Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extensionLihi Eder, Dafna D Gladman, Philip Mease, et al.
Rheumatology and Therapy|December 7, 2020
Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X TrialAtul Deodhar, Philip Mease, Proton Rahman, et al.
The New England Journal of Medicine|October 19, 2017
Tofacitinib or Adalimumab versus Placebo for Psoriatic ArthritisPhilip Mease, Stephen Hall, Oliver FitzGerald, et al.
The Journal of Investigative Dermatology|January 26, 2025
Construct Validity of the IDEOM Musculoskeletal Questionnaire: An Instrument to Measure Musculoskeletal Symptoms in Patients with Psoriatic DiseaseLourdes M Perez-Chada, George Gondo, Carly Grant, et al.
Arthritis and Rheumatism|December 4, 2010
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trialPhilip Mease, Mark C Genovese, Geoffrey Gladstein, et al.
Pageof 18